MedTrace Logo

Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

NCT05697575 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 336

Last updated 2026-04-13

No results posted yet for this study

Summary

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Conditions

  • Acute Stroke

Sponsors & Collaborators

  • National Society for Neurosonology and Cerebral Circulation

    lead OTHER

Principal Investigators

  • Igor A Voznjuk, Prof · First St. Petersburg State Medical University named after I.P. Pavlov

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2030-02-01
Completion
2030-05-10

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05697575 on ClinicalTrials.gov